FI3573631T3 - Ulostemikrobisto hematopoieettisten kantassolujen siirron saavien potilaiden hoitoon - Google Patents
Ulostemikrobisto hematopoieettisten kantassolujen siirron saavien potilaiden hoitoon Download PDFInfo
- Publication number
- FI3573631T3 FI3573631T3 FIEP18702952.5T FI18702952T FI3573631T3 FI 3573631 T3 FI3573631 T3 FI 3573631T3 FI 18702952 T FI18702952 T FI 18702952T FI 3573631 T3 FI3573631 T3 FI 3573631T3
- Authority
- FI
- Finland
- Prior art keywords
- transplant
- patient
- sample
- fecal microbiota
- hsc
- Prior art date
Links
- 210000003958 hematopoietic stem cell Anatomy 0.000 title claims 86
- 241000736262 Microbiota Species 0.000 title claims 82
- 230000002550 fecal effect Effects 0.000 title claims 81
- 239000000523 sample Substances 0.000 claims 63
- 238000002054 transplantation Methods 0.000 claims 28
- 238000011282 treatment Methods 0.000 claims 28
- 208000015181 infectious disease Diseases 0.000 claims 26
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 25
- 235000002639 sodium chloride Nutrition 0.000 claims 22
- 239000000243 solution Substances 0.000 claims 21
- 230000003750 conditioning effect Effects 0.000 claims 18
- 230000002458 infectious effect Effects 0.000 claims 18
- 239000000203 mixture Substances 0.000 claims 17
- 239000011780 sodium chloride Substances 0.000 claims 17
- 241000894006 Bacteria Species 0.000 claims 16
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims 16
- 239000002577 cryoprotective agent Substances 0.000 claims 16
- 239000007864 aqueous solution Substances 0.000 claims 13
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 12
- 206010028980 Neoplasm Diseases 0.000 claims 12
- 201000010099 disease Diseases 0.000 claims 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 12
- 238000011316 allogeneic transplantation Methods 0.000 claims 10
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 9
- 239000004067 bulking agent Substances 0.000 claims 9
- 230000001400 myeloablative effect Effects 0.000 claims 9
- 230000001154 acute effect Effects 0.000 claims 8
- 238000002512 chemotherapy Methods 0.000 claims 8
- 238000007710 freezing Methods 0.000 claims 8
- 230000008014 freezing Effects 0.000 claims 8
- 230000003211 malignant effect Effects 0.000 claims 8
- 230000001580 bacterial effect Effects 0.000 claims 7
- 210000003995 blood forming stem cell Anatomy 0.000 claims 7
- 201000011510 cancer Diseases 0.000 claims 7
- 210000004027 cell Anatomy 0.000 claims 7
- 238000000034 method Methods 0.000 claims 7
- 230000002265 prevention Effects 0.000 claims 7
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims 6
- 229920002774 Maltodextrin Polymers 0.000 claims 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims 6
- 229920002472 Starch Polymers 0.000 claims 6
- 238000010257 thawing Methods 0.000 claims 6
- 241000588919 Citrobacter freundii Species 0.000 claims 5
- FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 claims 5
- 239000003963 antioxidant agent Substances 0.000 claims 5
- 230000003078 antioxidant effect Effects 0.000 claims 5
- 235000006708 antioxidants Nutrition 0.000 claims 5
- 210000001185 bone marrow Anatomy 0.000 claims 5
- 150000002016 disaccharides Chemical class 0.000 claims 5
- 229960000390 fludarabine Drugs 0.000 claims 5
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 claims 5
- 208000024908 graft versus host disease Diseases 0.000 claims 5
- 238000002156 mixing Methods 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 5
- 241000894007 species Species 0.000 claims 5
- 239000008107 starch Substances 0.000 claims 5
- 235000019698 starch Nutrition 0.000 claims 5
- 230000001225 therapeutic effect Effects 0.000 claims 5
- 229960001196 thiotepa Drugs 0.000 claims 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims 4
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 claims 4
- 208000037384 Clostridium Infections Diseases 0.000 claims 4
- 241000792859 Enema Species 0.000 claims 4
- 229960002092 busulfan Drugs 0.000 claims 4
- 230000007812 deficiency Effects 0.000 claims 4
- 239000007920 enema Substances 0.000 claims 4
- 229940095399 enema Drugs 0.000 claims 4
- 238000001914 filtration Methods 0.000 claims 4
- 239000012520 frozen sample Substances 0.000 claims 4
- 244000005709 gut microbiome Species 0.000 claims 4
- 230000001506 immunosuppresive effect Effects 0.000 claims 4
- 208000032839 leukemia Diseases 0.000 claims 4
- 229920005862 polyol Polymers 0.000 claims 4
- 150000003077 polyols Chemical group 0.000 claims 4
- 150000004043 trisaccharides Chemical class 0.000 claims 4
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims 3
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 3
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 3
- 206010002961 Aplasia Diseases 0.000 claims 3
- FGUUSXIOTUKUDN-IBGZPJMESA-N C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 Chemical compound C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 FGUUSXIOTUKUDN-IBGZPJMESA-N 0.000 claims 3
- 241000193403 Clostridium Species 0.000 claims 3
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims 3
- 241000588747 Klebsiella pneumoniae Species 0.000 claims 3
- 241000589517 Pseudomonas aeruginosa Species 0.000 claims 3
- 206010040047 Sepsis Diseases 0.000 claims 3
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims 3
- 108010059993 Vancomycin Proteins 0.000 claims 3
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims 3
- 239000003242 anti bacterial agent Substances 0.000 claims 3
- 229940088710 antibiotic agent Drugs 0.000 claims 3
- 210000000601 blood cell Anatomy 0.000 claims 3
- 230000001684 chronic effect Effects 0.000 claims 3
- 229960004397 cyclophosphamide Drugs 0.000 claims 3
- 238000000265 homogenisation Methods 0.000 claims 3
- 230000000813 microbial effect Effects 0.000 claims 3
- LJPYJRMMPVFEKR-UHFFFAOYSA-N prop-2-ynylurea Chemical compound NC(=O)NCC#C LJPYJRMMPVFEKR-UHFFFAOYSA-N 0.000 claims 3
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 claims 3
- 235000019187 sodium-L-ascorbate Nutrition 0.000 claims 3
- 239000011755 sodium-L-ascorbate Substances 0.000 claims 3
- 239000007787 solid Substances 0.000 claims 3
- 238000003860 storage Methods 0.000 claims 3
- 239000000725 suspension Substances 0.000 claims 3
- 239000011732 tocopherol Substances 0.000 claims 3
- 229960003165 vancomycin Drugs 0.000 claims 3
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 claims 3
- MYPYJXKWCTUITO-LYRMYLQWSA-O vancomycin(1+) Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C([O-])=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)[NH2+]C)[C@H]1C[C@](C)([NH3+])[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-O 0.000 claims 3
- 206010000830 Acute leukaemia Diseases 0.000 claims 2
- 206010009657 Clostridium difficile colitis Diseases 0.000 claims 2
- 206010054236 Clostridium difficile infection Diseases 0.000 claims 2
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims 2
- 108010036949 Cyclosporine Proteins 0.000 claims 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims 2
- 241000186394 Eubacterium Species 0.000 claims 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 2
- 206010062016 Immunosuppression Diseases 0.000 claims 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims 2
- 229930195725 Mannitol Natural products 0.000 claims 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims 2
- 229930006000 Sucrose Natural products 0.000 claims 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 2
- 239000000427 antigen Substances 0.000 claims 2
- 108091007433 antigens Proteins 0.000 claims 2
- 102000036639 antigens Human genes 0.000 claims 2
- 235000010323 ascorbic acid Nutrition 0.000 claims 2
- 239000011668 ascorbic acid Substances 0.000 claims 2
- 244000052616 bacterial pathogen Species 0.000 claims 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims 2
- 210000001072 colon Anatomy 0.000 claims 2
- 238000005138 cryopreservation Methods 0.000 claims 2
- 210000004443 dendritic cell Anatomy 0.000 claims 2
- 230000001079 digestive effect Effects 0.000 claims 2
- 230000002496 gastric effect Effects 0.000 claims 2
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 2
- 239000008103 glucose Substances 0.000 claims 2
- 230000007062 hydrolysis Effects 0.000 claims 2
- 238000006460 hydrolysis reaction Methods 0.000 claims 2
- 210000002865 immune cell Anatomy 0.000 claims 2
- 239000012642 immune effector Substances 0.000 claims 2
- 230000008105 immune reaction Effects 0.000 claims 2
- 210000000987 immune system Anatomy 0.000 claims 2
- 229940121354 immunomodulator Drugs 0.000 claims 2
- 230000006872 improvement Effects 0.000 claims 2
- 238000011534 incubation Methods 0.000 claims 2
- 210000000936 intestine Anatomy 0.000 claims 2
- 239000008101 lactose Substances 0.000 claims 2
- 239000000594 mannitol Substances 0.000 claims 2
- 235000010355 mannitol Nutrition 0.000 claims 2
- 239000000463 material Substances 0.000 claims 2
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 claims 2
- 229960000282 metronidazole Drugs 0.000 claims 2
- 230000002906 microbiologic effect Effects 0.000 claims 2
- 244000005700 microbiome Species 0.000 claims 2
- 230000007170 pathology Effects 0.000 claims 2
- 210000005259 peripheral blood Anatomy 0.000 claims 2
- 239000011886 peripheral blood Substances 0.000 claims 2
- 239000011148 porous material Substances 0.000 claims 2
- 230000003449 preventive effect Effects 0.000 claims 2
- 230000000069 prophylactic effect Effects 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 230000005855 radiation Effects 0.000 claims 2
- 238000005070 sampling Methods 0.000 claims 2
- 239000000600 sorbitol Substances 0.000 claims 2
- 210000000130 stem cell Anatomy 0.000 claims 2
- 239000005720 sucrose Substances 0.000 claims 2
- 208000024891 symptom Diseases 0.000 claims 2
- 229930003799 tocopherol Natural products 0.000 claims 2
- 235000019149 tocopherols Nutrition 0.000 claims 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 2
- QUEDXNHFTDJVIY-UHFFFAOYSA-N γ-tocopherol Chemical class OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-UHFFFAOYSA-N 0.000 claims 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims 1
- AEQDJSLRWYMAQI-UHFFFAOYSA-N 2,3,9,10-tetramethoxy-6,8,13,13a-tetrahydro-5H-isoquinolino[2,1-b]isoquinoline Chemical compound C1CN2CC(C(=C(OC)C=C3)OC)=C3CC2C2=C1C=C(OC)C(OC)=C2 AEQDJSLRWYMAQI-UHFFFAOYSA-N 0.000 claims 1
- DBTMGCOVALSLOR-UHFFFAOYSA-N 32-alpha-galactosyl-3-alpha-galactosyl-galactose Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(OC2C(C(CO)OC(O)C2O)O)OC(CO)C1O DBTMGCOVALSLOR-UHFFFAOYSA-N 0.000 claims 1
- 208000004998 Abdominal Pain Diseases 0.000 claims 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 1
- 241001531272 Agathobaculum desmolans Species 0.000 claims 1
- 102000015790 Asparaginase Human genes 0.000 claims 1
- 108010024976 Asparaginase Proteins 0.000 claims 1
- 208000035143 Bacterial infection Diseases 0.000 claims 1
- 108020004256 Beta-lactamase Proteins 0.000 claims 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 claims 1
- 241001202853 Blautia Species 0.000 claims 1
- 241000123777 Blautia obeum Species 0.000 claims 1
- 241001464894 Blautia producta Species 0.000 claims 1
- 206010065553 Bone marrow failure Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 1
- 241000193163 Clostridioides difficile Species 0.000 claims 1
- 241001140928 Clostridium sordelli Species 0.000 claims 1
- 206010010356 Congenital anomaly Diseases 0.000 claims 1
- 206010053138 Congenital aplastic anaemia Diseases 0.000 claims 1
- 229920002261 Corn starch Polymers 0.000 claims 1
- 229930105110 Cyclosporin A Natural products 0.000 claims 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 claims 1
- RXVWSYJTUUKTEA-UHFFFAOYSA-N D-maltotriose Natural products OC1C(O)C(OC(C(O)CO)C(O)C(O)C=O)OC(CO)C1OC1C(O)C(O)C(O)C(CO)O1 RXVWSYJTUUKTEA-UHFFFAOYSA-N 0.000 claims 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 claims 1
- 241000016537 Dorea longicatena Species 0.000 claims 1
- 241000194033 Enterococcus Species 0.000 claims 1
- 241000194032 Enterococcus faecalis Species 0.000 claims 1
- 241000588724 Escherichia coli Species 0.000 claims 1
- 201000004939 Fanconi anemia Diseases 0.000 claims 1
- 229930091371 Fructose Natural products 0.000 claims 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims 1
- 239000005715 Fructose Substances 0.000 claims 1
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 claims 1
- 206010017533 Fungal infection Diseases 0.000 claims 1
- 241000233866 Fungi Species 0.000 claims 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 241000862469 Holdemania Species 0.000 claims 1
- 241000862470 Holdemania filiformis Species 0.000 claims 1
- 241001674997 Hungatella hathewayi Species 0.000 claims 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 1
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 claims 1
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 claims 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- 208000026350 Inborn Genetic disease Diseases 0.000 claims 1
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 claims 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 206010025327 Lymphopenia Diseases 0.000 claims 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 208000031888 Mycoses Diseases 0.000 claims 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 1
- SQVRNKJHWKZAKO-PFQGKNLYSA-N N-acetyl-beta-neuraminic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-PFQGKNLYSA-N 0.000 claims 1
- 244000038458 Nepenthes mirabilis Species 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010033661 Pancytopenia Diseases 0.000 claims 1
- 208000000733 Paroxysmal Hemoglobinuria Diseases 0.000 claims 1
- 102100036050 Phosphatidylinositol N-acetylglucosaminyltransferase subunit A Human genes 0.000 claims 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims 1
- ZVGNESXIJDCBKN-WUIGKKEISA-N R-Tiacumicin B Natural products O([C@@H]1[C@@H](C)O[C@H]([C@H]([C@H]1O)OC)OCC1=CC=CC[C@H](O)C(C)=C[C@@H]([C@H](C(C)=CC(C)=CC[C@H](OC1=O)[C@@H](C)O)O[C@H]1[C@H]([C@@H](O)[C@H](OC(=O)C(C)C)C(C)(C)O1)O)CC)C(=O)C1=C(O)C(Cl)=C(O)C(Cl)=C1CC ZVGNESXIJDCBKN-WUIGKKEISA-N 0.000 claims 1
- 208000035415 Reinfection Diseases 0.000 claims 1
- 208000007660 Residual Neoplasm Diseases 0.000 claims 1
- 241000192031 Ruminococcus Species 0.000 claims 1
- 241000291327 Ruminococcus faecis Species 0.000 claims 1
- 241000202356 Ruminococcus lactaris Species 0.000 claims 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims 1
- 241000191940 Staphylococcus Species 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 1
- 206010057644 Testis cancer Diseases 0.000 claims 1
- 241000209140 Triticum Species 0.000 claims 1
- 235000021307 Triticum Nutrition 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 claims 1
- 230000002924 anti-infective effect Effects 0.000 claims 1
- 230000000259 anti-tumor effect Effects 0.000 claims 1
- 238000013459 approach Methods 0.000 claims 1
- 229940072107 ascorbate Drugs 0.000 claims 1
- 229960005070 ascorbic acid Drugs 0.000 claims 1
- 229960003272 asparaginase Drugs 0.000 claims 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-M asparaginate Chemical compound [O-]C(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-M 0.000 claims 1
- 210000003719 b-lymphocyte Anatomy 0.000 claims 1
- 208000022362 bacterial infectious disease Diseases 0.000 claims 1
- 230000009286 beneficial effect Effects 0.000 claims 1
- 230000008901 benefit Effects 0.000 claims 1
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 claims 1
- 102000006635 beta-lactamase Human genes 0.000 claims 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 claims 1
- 230000003115 biocidal effect Effects 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000001772 blood platelet Anatomy 0.000 claims 1
- 239000011575 calcium Substances 0.000 claims 1
- 229910052791 calcium Inorganic materials 0.000 claims 1
- 239000001110 calcium chloride Substances 0.000 claims 1
- 229910001628 calcium chloride Inorganic materials 0.000 claims 1
- 235000011148 calcium chloride Nutrition 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 230000002612 cardiopulmonary effect Effects 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 229940044683 chemotherapy drug Drugs 0.000 claims 1
- 229960001265 ciclosporin Drugs 0.000 claims 1
- 239000011362 coarse particle Substances 0.000 claims 1
- 239000013066 combination product Substances 0.000 claims 1
- 229940127555 combination product Drugs 0.000 claims 1
- 238000007596 consolidation process Methods 0.000 claims 1
- 239000000470 constituent Substances 0.000 claims 1
- 239000008120 corn starch Substances 0.000 claims 1
- 238000012937 correction Methods 0.000 claims 1
- 239000013078 crystal Substances 0.000 claims 1
- 238000009109 curative therapy Methods 0.000 claims 1
- 229940084983 cyclophosphamide 50 mg Drugs 0.000 claims 1
- 229960002433 cysteine Drugs 0.000 claims 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 1
- 235000018417 cysteine Nutrition 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- 239000000539 dimer Substances 0.000 claims 1
- 229960001760 dimethyl sulfoxide Drugs 0.000 claims 1
- 230000003292 diminished effect Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 230000008030 elimination Effects 0.000 claims 1
- 238000003379 elimination reaction Methods 0.000 claims 1
- 208000037902 enteropathy Diseases 0.000 claims 1
- 230000008029 eradication Effects 0.000 claims 1
- 210000003743 erythrocyte Anatomy 0.000 claims 1
- 210000004700 fetal blood Anatomy 0.000 claims 1
- ZVGNESXIJDCBKN-UUEYKCAUSA-N fidaxomicin Chemical compound O([C@@H]1[C@@H](C)O[C@H]([C@H]([C@H]1O)OC)OCC\1=C/C=C/C[C@H](O)/C(C)=C/[C@@H]([C@H](/C(C)=C/C(/C)=C/C[C@H](OC/1=O)[C@@H](C)O)O[C@H]1[C@H]([C@@H](O)[C@H](OC(=O)C(C)C)C(C)(C)O1)O)CC)C(=O)C1=C(O)C(Cl)=C(O)C(Cl)=C1CC ZVGNESXIJDCBKN-UUEYKCAUSA-N 0.000 claims 1
- 229960000628 fidaxomicin Drugs 0.000 claims 1
- 239000000706 filtrate Substances 0.000 claims 1
- 238000011354 first-line chemotherapy Methods 0.000 claims 1
- 229930182830 galactose Natural products 0.000 claims 1
- 210000005095 gastrointestinal system Anatomy 0.000 claims 1
- 208000016361 genetic disease Diseases 0.000 claims 1
- 230000002068 genetic effect Effects 0.000 claims 1
- 229940050410 gluconate Drugs 0.000 claims 1
- 150000004676 glycans Chemical class 0.000 claims 1
- 231100000226 haematotoxicity Toxicity 0.000 claims 1
- 208000014951 hematologic disease Diseases 0.000 claims 1
- 210000000777 hematopoietic system Anatomy 0.000 claims 1
- 208000034737 hemoglobinopathy Diseases 0.000 claims 1
- 239000008240 homogeneous mixture Substances 0.000 claims 1
- 229960000908 idarubicin Drugs 0.000 claims 1
- 230000006698 induction Effects 0.000 claims 1
- 238000011419 induction treatment Methods 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 208000018337 inherited hemoglobinopathy Diseases 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 230000000968 intestinal effect Effects 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 238000010253 intravenous injection Methods 0.000 claims 1
- 238000004898 kneading Methods 0.000 claims 1
- 210000000265 leukocyte Anatomy 0.000 claims 1
- 210000004698 lymphocyte Anatomy 0.000 claims 1
- 229910001629 magnesium chloride Inorganic materials 0.000 claims 1
- 235000011147 magnesium chloride Nutrition 0.000 claims 1
- 159000000003 magnesium salts Chemical class 0.000 claims 1
- 230000014759 maintenance of location Effects 0.000 claims 1
- FYGDTMLNYKFZSV-UHFFFAOYSA-N mannotriose Natural products OC1C(O)C(O)C(CO)OC1OC1C(CO)OC(OC2C(OC(O)C(O)C2O)CO)C(O)C1O FYGDTMLNYKFZSV-UHFFFAOYSA-N 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000010534 mechanism of action Effects 0.000 claims 1
- 230000002503 metabolic effect Effects 0.000 claims 1
- 229960000485 methotrexate Drugs 0.000 claims 1
- RTGDFNSFWBGLEC-SYZQJQIISA-N mycophenolate mofetil Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-SYZQJQIISA-N 0.000 claims 1
- 229960004866 mycophenolate mofetil Drugs 0.000 claims 1
- 201000000050 myeloid neoplasm Diseases 0.000 claims 1
- 230000002071 myeloproliferative effect Effects 0.000 claims 1
- 210000000822 natural killer cell Anatomy 0.000 claims 1
- 150000002482 oligosaccharides Polymers 0.000 claims 1
- 201000003045 paroxysmal nocturnal hemoglobinuria Diseases 0.000 claims 1
- 230000002093 peripheral effect Effects 0.000 claims 1
- 230000002085 persistent effect Effects 0.000 claims 1
- 229920001282 polysaccharide Polymers 0.000 claims 1
- 239000005017 polysaccharide Substances 0.000 claims 1
- 239000011591 potassium Substances 0.000 claims 1
- 229910052700 potassium Inorganic materials 0.000 claims 1
- 239000001103 potassium chloride Substances 0.000 claims 1
- 235000011164 potassium chloride Nutrition 0.000 claims 1
- 229920001592 potato starch Polymers 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 230000008569 process Effects 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 238000011084 recovery Methods 0.000 claims 1
- 230000004044 response Effects 0.000 claims 1
- 238000012552 review Methods 0.000 claims 1
- 238000011333 second-line chemotherapy Methods 0.000 claims 1
- 208000026775 severe diarrhea Diseases 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- 239000001632 sodium acetate Substances 0.000 claims 1
- 235000017281 sodium acetate Nutrition 0.000 claims 1
- 239000000176 sodium gluconate Substances 0.000 claims 1
- 235000012207 sodium gluconate Nutrition 0.000 claims 1
- 229940005574 sodium gluconate Drugs 0.000 claims 1
- 238000001228 spectrum Methods 0.000 claims 1
- 230000003019 stabilising effect Effects 0.000 claims 1
- 210000002784 stomach Anatomy 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 235000000346 sugar Nutrition 0.000 claims 1
- 150000008163 sugars Chemical class 0.000 claims 1
- 230000004083 survival effect Effects 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 230000002195 synergetic effect Effects 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 201000003120 testicular cancer Diseases 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 229960001295 tocopherol Drugs 0.000 claims 1
- 238000012546 transfer Methods 0.000 claims 1
- 239000013638 trimer Substances 0.000 claims 1
- 241001148471 unidentified anaerobic bacterium Species 0.000 claims 1
- 210000004291 uterus Anatomy 0.000 claims 1
- 230000035899 viability Effects 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
- 229940100445 wheat starch Drugs 0.000 claims 1
- FYGDTMLNYKFZSV-BYLHFPJWSA-N β-1,4-galactotrioside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@H](CO)O[C@@H](O[C@@H]2[C@@H](O[C@@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-BYLHFPJWSA-N 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR1750629A FR3062063B1 (fr) | 2017-01-26 | 2017-01-26 | Microbiote fecal pour traiter des patients subissant une greffe de cellules souches hematopoietiques |
| PCT/EP2018/051941 WO2018138251A1 (fr) | 2017-01-26 | 2018-01-26 | Microbiote fecal pour traiter des patients subissant une greffe de cellules souches hematopoietiques |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FI3573631T3 true FI3573631T3 (fi) | 2023-03-02 |
Family
ID=59325347
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP18702952.5T FI3573631T3 (fi) | 2017-01-26 | 2018-01-26 | Ulostemikrobisto hematopoieettisten kantassolujen siirron saavien potilaiden hoitoon |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20200188450A1 (enExample) |
| EP (1) | EP3573631B1 (enExample) |
| JP (1) | JP7527109B2 (enExample) |
| KR (1) | KR102517287B1 (enExample) |
| CN (1) | CN110520141A (enExample) |
| AU (1) | AU2018212530B2 (enExample) |
| CA (1) | CA3051807C (enExample) |
| DK (1) | DK3573631T3 (enExample) |
| ES (1) | ES2937965T3 (enExample) |
| FI (1) | FI3573631T3 (enExample) |
| FR (1) | FR3062063B1 (enExample) |
| HR (1) | HRP20230122T1 (enExample) |
| HU (1) | HUE061155T2 (enExample) |
| IL (1) | IL268237B (enExample) |
| LT (1) | LT3573631T (enExample) |
| PL (1) | PL3573631T3 (enExample) |
| PT (1) | PT3573631T (enExample) |
| RS (1) | RS63978B1 (enExample) |
| SI (1) | SI3573631T1 (enExample) |
| WO (1) | WO2018138251A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3072032A1 (en) * | 2017-08-07 | 2019-02-14 | Finch Therapeutics, Inc. | Compositions and methods for maintaining and restoring a healthy gut barrier |
| US20220023419A1 (en) * | 2018-11-28 | 2022-01-27 | The Council Of The Queensland Institute Of Medical Research | Inhibiting inflammation |
| CN112375705A (zh) * | 2020-11-12 | 2021-02-19 | 安徽燕婉健康科技有限公司 | 一种替代天然菌群的肠壁移植优势菌的制备方法及其应用 |
| EP4386090A1 (en) * | 2022-12-12 | 2024-06-19 | Assistance Publique - Hôpitaux De Paris | Method for determining and improving the potential efficacy of anticancer treatment |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2649719B1 (fr) * | 1989-07-17 | 1993-08-27 | Cerbio Sa | Procede de protection et de conservation de micro-organismes notamment de bacteries |
| CN103561752B (zh) * | 2011-03-09 | 2016-04-20 | 明尼苏达大学评议会 | 用于移植结肠微生物群的组合物和方法 |
| JP2016501852A (ja) * | 2012-11-26 | 2016-01-21 | トーマス・ジュリアス・ボロディ | 糞便微生物叢の回復のための組成物、ならびにそれらを作製および使用する方法 |
| US10046030B2 (en) * | 2014-10-07 | 2018-08-14 | University Of Virginia Patent Foundation | Compositions and methods for preventing and treating infection |
| AU2015353465B2 (en) * | 2014-11-25 | 2021-07-29 | Memorial Sloan-Kettering Cancer Center | Intestinal microbiota and GVHD |
| MA41020A (fr) * | 2014-11-25 | 2017-10-03 | Evelo Biosciences Inc | Compositions probiotiques et prébiotiques, et leurs procédés d'utilisation pour la modulation du microbiome |
| FR3035328B1 (fr) * | 2015-04-24 | 2019-08-23 | Maat Pharma | Procede de preparation d'un echantillon de microbiote fecal |
| JP6408092B2 (ja) * | 2016-08-29 | 2018-10-17 | 国立大学法人 東京大学 | 糞便微生物叢を含む組成物 |
-
2017
- 2017-01-26 FR FR1750629A patent/FR3062063B1/fr not_active Expired - Fee Related
-
2018
- 2018-01-26 WO PCT/EP2018/051941 patent/WO2018138251A1/fr not_active Ceased
- 2018-01-26 HU HUE18702952A patent/HUE061155T2/hu unknown
- 2018-01-26 US US16/480,863 patent/US20200188450A1/en not_active Abandoned
- 2018-01-26 LT LTEPPCT/EP2018/051941T patent/LT3573631T/lt unknown
- 2018-01-26 IL IL268237A patent/IL268237B/en unknown
- 2018-01-26 SI SI201830842T patent/SI3573631T1/sl unknown
- 2018-01-26 CN CN201880008477.0A patent/CN110520141A/zh active Pending
- 2018-01-26 CA CA3051807A patent/CA3051807C/fr active Active
- 2018-01-26 PT PT187029525T patent/PT3573631T/pt unknown
- 2018-01-26 KR KR1020197024970A patent/KR102517287B1/ko active Active
- 2018-01-26 RS RS20230101A patent/RS63978B1/sr unknown
- 2018-01-26 FI FIEP18702952.5T patent/FI3573631T3/fi active
- 2018-01-26 ES ES18702952T patent/ES2937965T3/es active Active
- 2018-01-26 JP JP2019540408A patent/JP7527109B2/ja active Active
- 2018-01-26 EP EP18702952.5A patent/EP3573631B1/fr active Active
- 2018-01-26 AU AU2018212530A patent/AU2018212530B2/en active Active
- 2018-01-26 DK DK18702952.5T patent/DK3573631T3/da active
- 2018-01-26 HR HRP20230122TT patent/HRP20230122T1/hr unknown
- 2018-01-26 PL PL18702952.5T patent/PL3573631T3/pl unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3051807A1 (fr) | 2018-08-02 |
| LT3573631T (lt) | 2023-03-10 |
| FR3062063B1 (fr) | 2019-04-19 |
| SI3573631T1 (sl) | 2023-09-29 |
| DK3573631T3 (da) | 2023-01-30 |
| AU2018212530A1 (en) | 2019-09-05 |
| JP7527109B2 (ja) | 2024-08-02 |
| HUE061155T2 (hu) | 2023-05-28 |
| EP3573631B1 (fr) | 2022-11-16 |
| IL268237A (en) | 2019-09-26 |
| KR20190130563A (ko) | 2019-11-22 |
| PT3573631T (pt) | 2023-01-24 |
| ES2937965T3 (es) | 2023-04-03 |
| CA3051807C (fr) | 2023-07-11 |
| HRP20230122T1 (hr) | 2023-03-31 |
| JP2020506183A (ja) | 2020-02-27 |
| CN110520141A (zh) | 2019-11-29 |
| KR102517287B1 (ko) | 2023-03-31 |
| RS63978B1 (sr) | 2023-03-31 |
| WO2018138251A1 (fr) | 2018-08-02 |
| IL268237B (en) | 2022-07-01 |
| FR3062063A1 (fr) | 2018-07-27 |
| EP3573631A1 (fr) | 2019-12-04 |
| US20200188450A1 (en) | 2020-06-18 |
| PL3573631T3 (pl) | 2023-05-02 |
| AU2018212530B2 (en) | 2022-06-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102341203B1 (ko) | 분변 미생물총의 샘플의 동결건조 방법 | |
| CN107530280B (zh) | 粪便微生物群样品的制备方法 | |
| Harish et al. | Probiotics in humans–evidence based review | |
| AU2012229902B2 (en) | Immunogenic composition for immune system modulation and use thereof, method for treating and preventing diseases, method for inducing cell regeneration and method for restoring immune response | |
| AU2018212530B2 (en) | Fecal microbiota for treating patients undergoing a hematopoietic stem cell transplant | |
| BR112020017090A2 (pt) | Imunoterapias relacionadas com microbioma | |
| CN104918624A (zh) | 恢复排泄物微生物群的组合物及其制造和使用方法 | |
| AU2019229721A1 (en) | Stool collection method and sample preparation method for transplanting fecal microbiota | |
| US20200038459A1 (en) | Composition comprising fecal microbiota | |
| JP2020526583A5 (enExample) | ||
| Daniluk et al. | Probiotic-induced apoptosis and its potential relevance to mucosal inflammation of gastrointestinal tract | |
| Sung et al. | Double high-dose chemotherapy with autologous stem cell transplantation in patients with high-risk neuroblastoma: a pilot study in a single center | |
| Sinitsyn et al. | Combined bone marrow and peripheral blood progenitor cell autografts for patients with poor mobilization | |
| Park et al. | Improved survival in patients with recurrent Wilms tumor: the experience of the Seoul National University Children's Hospital | |
| Parikh et al. | Reduced-intensity conditioning (RIC) in children with nonmalignant disorders (NMD) undergoing unrelated donor umbilical cord blood transplantation (UCBT) | |
| Schneiderman et al. | 222: Donor Chimerism Kinetics in Pediatric Patients Undergoing Reduced Intensity Conditioning (RIC) with Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) | |
| Kennedy-Nasser et al. | 223: Alternative Donor Hematopoietic Stem Cell Transplantation for Pediatric Patients with Acute Lymphoblastic Leukemia Using Campath in a Myeloablative Conditioning Regimen | |
| Alvaro et al. | Leak Treatment in Pancreas Transplant: 753 | |
| Kebriaei et al. | Inferior Outcome With Addition Of Rituximab For Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) In Acute Lymphoblastic Leukemia (ALL) | |
| Grochowiecki et al. | The Timing and a Cause of the Graft Pancreatectomy Has an Impact on the Simultaneous Pancreas and Kidney Recipient Survival: 449 | |
| Kido et al. | Allogeneic and autologous stem cell transplantation in advanced small round cell sarcomas | |
| Wingard | Past, Present, Future | |
| Hamidieh et al. | Results of Hematopoietic Stem Cell Transplantation In Patients with Leukocyte Adhesion Deficiency Type I |